July 2017- Volume 13, Issue 7
In this Issue
Clinical Trials
Recruitment in practice
Recruitment in practice
With a eye on general practitioners, Interface Clinical Research looks to reduce patient dropout rates and rescue failed trials
Novo Nordisk unveils Tresiba results
Novo Nordisk unveils Tresiba results
Diabetes therapeutic reportedly superior to insulin glargine in reducing hypoglycemia, without raising cardiovascular risk
OmniComm expands global reach with new deals
OmniComm expands global reach with new deals
TrialOne system to standardize clinical development programs, ensure regulatory compliance and bring greater operational efficiency
Good news regarding diabetes and high cholesterol
Good news regarding diabetes and high cholesterol
Sanofi and Regeneron announce positive results from first dedicated studies evaluating Praluent in individuals with diabetes and hypercholesterolemia
Contract Services
CRO consolidation
CRO consolidation
International CRO acquisition deals popular in Q2
Streamlining drug discovery
Streamlining drug discovery
Dotmatics informatics services expected to aid integrated research capabilities at Domainex
Whole greater than the sum?
Whole greater than the sum?
Two Rentschler holdings join forces for state-of-the-art biopharmaceutical development and delivery
Business & Government Policy
It’s all about timing
It’s all about timing
Supreme Court rules that market announcements for biosimilars can come before approval in Sandoz v. Amgen
EMA shares meeting highlights
EMA shares meeting highlights
Focus was on Brexit preparations and development of the EU clinical trial portal and database
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Moving fusion proteins forward
Moving fusion proteins forward
Selexis announces commercial license agreement with Takeda for the development of fusion proteins
BIO 2017 wrap-up
BIO 2017 wrap-up
A quick look at the recent BIO International Convention and what the event offers to attendees
Discovery
Exscientia and Sanofi get specific with €250M deal
Exscientia and Sanofi get specific with €250M deal
Companies enter into collaboration aimed at developing bispecific small-molecule drugs
‘Artificial’ discovery
‘Artificial’ discovery
BioXcel creates new artificial intelligence company to power biotech and pharma R&D
Allergen breakthrough marks 50th anniversary
Allergen breakthrough marks 50th anniversary
Thermo Fisher Scientific celebrates the discovery of the immunoglobulin antibody, which triggered five decades of innovation in allergy and asthma diagnosis and treatment
Trying to gain on glioblastoma
Trying to gain on glioblastoma
Sweden’s Beactica and Uppsala University launch research to find a way to treat and beat brain cancer
Diagnostics
PEPperPRINT and PROGEN to develop novel RA test
PEPperPRINT and PROGEN to develop novel RA test
SeroRA antigen library will reportedly enable superior rheumatoid arthritis biomarker screening
Reading tea leaves? No, reading stools
Reading tea leaves? No, reading stools
Research by UC San Diego, Human Longevity and JCVI finds stool microbes predict advanced liver disease
Positive results for PromarkerD
Positive results for PromarkerD
Proteomics International says new blood test can detect diabetic kidney disease earlier than any other method
Research & Development
Hope on the horizon
Hope on the horizon
Public-private partnership teams up for trauma-related brain disorders
Bringing the data for precision medicine
Bringing the data for precision medicine
IBM and tranSMART bring tech together for translational work; tranSMART announces merger with i2b2
OSE teams with Memorial Sloan Kettering
OSE teams with Memorial Sloan Kettering
Multiyear research collaboration focused on cytotoxic monoclonal antibody OSE-703
New options against HIV
New options against HIV
TSRI shares success in viral research and vaccine development
Preclinical
A contender against AML
A contender against AML
Partner organizations present preclinical data supporting superiority of CG’806 to fight AML
Isarna eyes glaucoma and AMD/DME treatment potential
Isarna eyes glaucoma and AMD/DME treatment potential
Preclinical results, clinical data support further exploration of ISTH0036 in several ophthalmic indications
Novel antibody drug class could mean faster arrival of immunotherapies
Novel antibody drug class could mean faster arrival of immunotherapies
Nature Medicine reports elimination of large tumors in mice by messenger rna-encoded bispecific antibodies
Repurposing research
Repurposing research
NCATS and UNR researchers use compound for experimental cancer therapy to treat muscular dystrophy
Feature
Special Focus on Cancer Research News: A glance back and a gaze forward on glyco
Special Focus on Cancer Research News: A glance back and a gaze forward on glyco
Looking at glycobiology with relation to cancer, plus more in recent oncology R&D news
Show Preview: Immuno-Oncology Summit--Exploring the next generation of IO
Show Preview: Immuno-Oncology Summit--Exploring the next generation of IO
Immuno-Oncology Summit looks at how to apply new science and technology in developing effective and safe immunotherapies
Editor's Focus
Preclinical perils and clinical catastrophe
Preclinical perils and clinical catastrophe
Human-relevant non-animal models are becoming ever more relevant and ever more advanced (and thus need more attention from FDA), but they won't prevent or probably much reduce clinical trial mortality, and it's not clear that they will (or should) completely replace animal models
Commentary
Out of order: A word about communication
Out of order: A word about communication
In the vein of 'garbage in, garbage out' from the computer programming world, perhaps we also need to think in terms of 'jargon in, gibberish out' a bit more often with scientific discussions
Guest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
Guest Commentary: Planning successful oncology trials amid a rapidly shifting treatment landscape
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes
